Deficient histone H3 propionylation by BRPF1-KAT6 complexes in neurodevelopmental disorders and cancer

神经发育障碍和癌症中BRPF1-KAT6复合物介导的组蛋白H3丙酰化不足

阅读:1
作者:Kezhi Yan ,Justine Rousseau ,Keren Machol ,Laura A Cross ,Katherine E Agre ,Cynthia Forster Gibson ,Anne Goverde ,Kendra L Engleman ,Hannah Verdin ,Elfride De Baere ,Lorraine Potocki ,Dihong Zhou ,Maxime Cadieux-Dion ,Gary A Bellus ,Monisa D Wagner ,Rebecca J Hale ,Natacha Esber ,Alan F Riley ,Benjamin D Solomon ,Megan T Cho ,Kirsty McWalter ,Roy Eyal ,Meagan K Hainlen ,Bryce A Mendelsohn ,Hillary M Porter ,Brendan C Lanpher ,Andrea M Lewis ,Juliann Savatt ,Isabelle Thiffault ,Bert Callewaert ,Philippe M Campeau ,Xiang-Jiao Yang

Abstract

Lysine acetyltransferase 6A (KAT6A) and its paralog KAT6B form stoichiometric complexes with bromodomain- and PHD finger-containing protein 1 (BRPF1) for acetylation of histone H3 at lysine 23 (H3K23). We report that these complexes also catalyze H3K23 propionylation in vitro and in vivo. Immunofluorescence microscopy and ATAC-See revealed the association of this modification with active chromatin. Brpf1 deletion obliterates the acylation in mouse embryos and fibroblasts. Moreover, we identify BRPF1 variants in 12 previously unidentified cases of syndromic intellectual disability and demonstrate that these cases and known BRPF1 variants impair H3K23 propionylation. Cardiac anomalies are present in a subset of the cases. H3K23 acylation is also impaired by cancer-derived somatic BRPF1 mutations. Valproate, vorinostat, propionate and butyrate promote H3K23 acylation. These results reveal the dual functionality of BRPF1-KAT6 complexes, shed light on mechanisms underlying related developmental disorders and various cancers, and suggest mutation-based therapy for medical conditions with deficient histone acylation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。